Ventyx Biosciences, Inc.
DelistedCIK 1851194fmd_10VR37Y1JYPHW7NPV7YX30EWJ9Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Sep 30, 2025, 21 periods
Latest annual · FY2024
Millions- Operating income
- (148)
- Net income
- (135)
- Free cash flow
- (131)
Latest quarter · Q3 FY2025
Millions- Operating income
- (25)
- Net income
- (23)
- Free cash flow
- (18)
Ventyx Biosciences, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2024 | FY2023 | Change | Source |
|---|---|---|---|---|
| Operating income | -$148.5 million | -$208 million | 10-K 2025-02-27 · proof | |
| Net income | -$135.1 million | -$193 million | 10-K 2025-02-27 · proof | |
| Cash from operating activities | -$130.9 million | -$166.5 million | 10-K 2025-02-27 · proof | |
| Free cash flow | -$131.1 million | -$167 million | 10-K 2025-02-27 · proof | |
| Total assets | $276.6 million | $277.7 million | -0.4% | 10-K 2025-02-27 · proof |
| Total liabilities | $22.5 million | $33.8 million | -33.3% | 10-K 2025-02-27 · proof |
| Cash and cash equivalents | $27.3 million | $51.6 million | -47.1% | 10-K 2025-02-27 · proof |
- What was Ventyx Biosciences, Inc.'s operating income in fiscal 2024?
- Ventyx Biosciences, Inc. reported operating income of -$148.5 million for fiscal 2024 (the year ended Dec 31, 2024), against -$208 million the year before. Source: the 10-K filed with the SEC on Feb 27, 2025. SEC
- What was Ventyx Biosciences, Inc.'s net income in fiscal 2024?
- Ventyx Biosciences, Inc. reported net income of -$135.1 million for fiscal 2024 (the year ended Dec 31, 2024), against -$193 million the year before. Source: the 10-K filed with the SEC on Feb 27, 2025. SEC
- What was Ventyx Biosciences, Inc.'s cash from operating activities in fiscal 2024?
- Ventyx Biosciences, Inc. reported cash from operating activities of -$130.9 million for fiscal 2024 (the year ended Dec 31, 2024), against -$166.5 million the year before. Source: the 10-K filed with the SEC on Feb 27, 2025. SEC
- What was Ventyx Biosciences, Inc.'s free cash flow in fiscal 2024?
- Ventyx Biosciences, Inc. reported free cash flow of -$131.1 million for fiscal 2024 (the year ended Dec 31, 2024), against -$167 million the year before. Source: the 10-K filed with the SEC on Feb 27, 2025. SEC
- What are Ventyx Biosciences, Inc.'s total assets?
- As of Dec 31, 2024, Ventyx Biosciences, Inc. reported total assets of $276.6 million, against $277.7 million a year earlier (-0.4%). Source: the 10-K filed with the SEC on Feb 27, 2025. SEC
- What are Ventyx Biosciences, Inc.'s total liabilities?
- As of Dec 31, 2024, Ventyx Biosciences, Inc. reported total liabilities of $22.5 million, against $33.8 million a year earlier (-33.3%). Source: the 10-K filed with the SEC on Feb 27, 2025. SEC
- What are Ventyx Biosciences, Inc.'s cash and cash equivalents?
- As of Dec 31, 2024, Ventyx Biosciences, Inc. reported cash and cash equivalents of $27.3 million, against $51.6 million a year earlier (-47.1%). Source: the 10-K filed with the SEC on Feb 27, 2025. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1851194&period_type=annual&limit=5"Information only, not investment advice.